Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Irwin

Showing results (21-30 of 161) with videos related to

Pageof 17
Sort By:
Peptides|February 8, 2018
Emerging therapeutic potential for peptide YY for obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Clinical Medicine Insights. Endocrinology and Diabetes|September 30, 2021
Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic DisordersSarah L Craig, Nigel Irwin, Victor A Gault
Biological Chemistry|August 20, 2011
Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in ratsNigel Irwin, Jacqueline M E Francis, Peter R Flatt
Expert Review of Endocrinology & Metabolism|October 6, 2018
Effects of anti-diabetic drugs on bone metabolismGuillaume Mabilleau, Daniel Chappard, Peter R Flatt, et al.
International Journal of Molecular Sciences|May 14, 2025
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell LineageWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Peptides|September 15, 2023
An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disordersDaniel M Gallagher, Finbarr P M O'Harte, Nigel Irwin
European Journal of Pharmacology|April 9, 2013
desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activityNigel Irwin, Zara J Franklin, Finbarr P M O'Harte
European Journal of Pharmacology|January 15, 2008
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) miceNigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Peptides|December 12, 2022
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetesWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Biological Chemistry|November 9, 2013
Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in miceZara J Franklin, Finbarr P M O'Harte, Nigel Irwin
Pageof 17

Showing results (21-30 of 161) with videos related to

Sort By:
Pageof 17
Peptides|February 8, 2018
Emerging therapeutic potential for peptide YY for obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Clinical Medicine Insights. Endocrinology and Diabetes|September 30, 2021
Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic DisordersSarah L Craig, Nigel Irwin, Victor A Gault
Biological Chemistry|August 20, 2011
Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in ratsNigel Irwin, Jacqueline M E Francis, Peter R Flatt
Expert Review of Endocrinology & Metabolism|October 6, 2018
Effects of anti-diabetic drugs on bone metabolismGuillaume Mabilleau, Daniel Chappard, Peter R Flatt, et al.
International Journal of Molecular Sciences|May 14, 2025
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell LineageWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Peptides|September 15, 2023
An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disordersDaniel M Gallagher, Finbarr P M O'Harte, Nigel Irwin
European Journal of Pharmacology|April 9, 2013
desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activityNigel Irwin, Zara J Franklin, Finbarr P M O'Harte
European Journal of Pharmacology|January 15, 2008
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) miceNigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Peptides|December 12, 2022
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetesWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Biological Chemistry|November 9, 2013
Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in miceZara J Franklin, Finbarr P M O'Harte, Nigel Irwin
Pageof 17